Publicacions en col·laboració amb investigadors/es de University of Alabama at Birmingham (41)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  3. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  4. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  5. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast

    Advances in Therapy

  6. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

  4. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

  5. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818

  3. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  4. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

  5. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310

  6. Trial of Prasinezumab in Early-Stage Parkinson's Disease

    New England Journal of Medicine, Vol. 387, Núm. 5, pp. 421-432

  7. Variations in management of A3 and A4 cervical spine fractures as designated by the AO Spine Subaxial Injury Classification System

    Journal of Neurosurgery: Spine, Vol. 36, Núm. 1, pp. 99-112

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382